Building a better world
Europe’s most successful science park
A vibrant community of like-minded people
Combining science and nature
Visiting the park
Next bus departing
A - Trumpington, Cambridge
Leaving The Busway Science Park
D - St Ives
Leaving The Busway Science Park
D - Trumpington, Cambridge
Leaving The Busway Science Park
A - St Ives
Leaving The Busway Science Park
Next train departing
11:21 - London Liverpool Street
Leaving Cambridge
11:24 - Cambridge
Leaving Cambridge North
11:27 - London Kings Cross
Leaving Cambridge
11:30 - Stansted Airport
Leaving Cambridge
About the Cambridge Science Park
The Cambridge Science Park was established 48 years ago when Trinity College Cambridge embraced the concept that would change the hi-tech sector in Cambridge, the UK and beyond. Trinity owns the freehold of the Cambridge Science Park, which today comprises 150 acres, 1.7 million sq ft of high technology and laboratory buildings. It’s home to 7500 people at over 100 companies, ranging from exciting start-ups to some of the world's leading technology businesses.
Over 100 entrepreneurial businesses
Companies and entrepreneurs at the Cambridge Science Park are working on life-enhancing technologies, ranging from non-invasive diagnostics and novel medicines to next-generation display and communications technologies, to name just a few. The wide range of occupiers in terms of size, sector, age and nationality offers unrivalled opportunities for collaboration, innovation and inspiration.
-
Worldpay Ltd
Technology
-
GEMA Digital UK Ltd
Technology
-
Nuclera
Life Sciences
-
Grant Thornton
Business support services
-
Owlstone Medical Ltd
Life Sciences
-
IP21
Business support services
-
Cambridge Assessment
Business support services
-
Abbexa Ltd
Life Sciences
-
Mind The Product Ltd
Technology
-
Spectral Edge
Technology
-
Broadcom Ltd
Technology
-
Everynet
Technology
The latest news, discoveries and innovations
See all newsTWEET by @Agenus_Bio
Welcome Don Vidic as Head of Commercial. Don is an innovator & expert in market access & distribution. He joins to actualize our commitment to disruptive commercial models designed to provide access to all patients who need our products. investor.agenusbio.com/2019-07-18-Age…
TWEET by @Amgen
#Amgen and @Allergan have launched two first of their kind oncology #biosimilar products in the U.S.: bit.ly/32AygaP
Contact us
Thank you for your enquiry!
We'll be in touch soon.